AMG National Trust Bank Lowers Stock Holdings in Danaher Co. (NYSE:DHR)

AMG National Trust Bank reduced its stake in shares of Danaher Co. (NYSE:DHR - Free Report) by 24.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,534 shares of the conglomerate's stock after selling 6,618 shares during the quarter. AMG National Trust Bank's holdings in Danaher were worth $5,708,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in DHR. Benjamin Edwards Inc. grew its holdings in Danaher by 1.8% in the 2nd quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate's stock valued at $538,000 after buying an additional 38 shares in the last quarter. Wedge Capital Management L L P NC lifted its stake in Danaher by 3.2% during the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate's stock worth $342,000 after acquiring an additional 38 shares in the last quarter. Patrick M Sweeney & Associates Inc. lifted its stake in Danaher by 3.4% during the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate's stock worth $307,000 after acquiring an additional 40 shares in the last quarter. Trust Co of Kansas lifted its stake in Danaher by 4.1% during the 2nd quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate's stock worth $255,000 after acquiring an additional 40 shares in the last quarter. Finally, Abacus Planning Group Inc. raised its position in Danaher by 0.7% in the 2nd quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate's stock valued at $1,359,000 after purchasing an additional 40 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. UBS Group reduced their price target on Danaher from $309.00 to $305.00 and set a "buy" rating on the stock in a research report on Wednesday, October 23rd. Stifel Nicolaus raised their price target on Danaher from $250.00 to $265.00 and gave the stock a "hold" rating in a research note on Wednesday, October 23rd. Evercore ISI lifted their target price on Danaher from $275.00 to $278.00 and gave the company an "outperform" rating in a research note on Tuesday, October 1st. Royal Bank of Canada lowered their target price on Danaher from $333.00 to $311.00 and set an "outperform" rating on the stock in a research note on Wednesday, October 23rd. Finally, Bank of America lifted their target price on Danaher from $270.00 to $275.00 and gave the company a "neutral" rating in a research note on Wednesday, July 24th. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $287.16.

Danaher Price Performance

DHR stock traded down $1.00 during midday trading on Monday, hitting $229.50. 3,932,732 shares of the stock were exchanged, compared to its average volume of 2,764,637. The stock's 50-day moving average price is $261.33 and its 200-day moving average price is $260.45. The stock has a market cap of $165.76 billion, a price-to-earnings ratio of 43.80, a PEG ratio of 4.24 and a beta of 0.85. Danaher Co. has a fifty-two week low of $207.63 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to analysts' expectations of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. Danaher's revenue was up 3.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.02 earnings per share. Research analysts predict that Danaher Co. will post 7.51 earnings per share for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a $0.27 dividend. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.47%. Danaher's dividend payout ratio (DPR) is 20.61%.

Insider Transactions at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the business's stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company's stock, valued at $1,130,374.44. The trade was a 18.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 11.10% of the company's stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.